Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 138000
Corporate User License Price USD 6000
Corporate User License Price INR 414000
Site License Price USD 4000
Site License Price INR 276000
Request a Quote

Report Title

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017



Executive Summary

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 54, 25, 1, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).

The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

Introduction

Bile Duct Cancer (Cholangiocarcinoma)-Overview

Bile Duct Cancer (Cholangiocarcinoma)-Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma)-Therapeutics Assessment

Bile Duct Cancer (Cholangiocarcinoma)-Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma)-Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma)-Discontinued Products 740

Bile Duct Cancer (Cholangiocarcinoma)-Product Development Milestones

Appendix

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by 4SC AG, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Advenchen Laboratories LLC, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Agios Pharmaceuticals Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Ariad Pharmaceuticals Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by ArQule Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Array BioPharma Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by AstraZeneca Plc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Bavarian Nordic A/S, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Bayer AG, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by BeiGene Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Boston Biomedical Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Bristol-Myers Squibb Co, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Celgene Corp, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Celldex Therapeutics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Cellular Biomedicine Group Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by CytomX Therapeutics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Debiopharm International SA, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Delcath Systems Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Eisai Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Eli Lilly and Co, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Exelixis Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Genentech Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Genoscience Pharma, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by H3 Biomedicine Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Halozyme Therapeutics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Hutchison MediPharma Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Ignyta Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Immunitor Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Incyte Corp, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Innopharmax Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Ipsen SA, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Johnson & Johnson, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Komipharm International Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Leap Therapeutics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Loxo Oncology Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Mebiopharm Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by MedImmune LLC, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Merck & Co Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Molecular Templates Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Mundipharma International Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by NanoCarrier Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by NormOxys Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Novartis AG, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by NuCana Plc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Oasmia Pharmaceutical AB, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by OncoTherapy Science Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Panacea Pharmaceuticals Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by PCI Biotech Holding ASA, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Pfizer Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Pharma Mar SA, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Plexxikon Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Provecs Medical GmbH (Inactive), H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Puma Biotechnology Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Rafael Pharmaceuticals Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by RedHill Biopharma Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Redx Pharma Plc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Sanofi, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Senhwa Biosciences Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Sirnaomics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by SynCore Biotechnology Co Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Syndax Pharmaceuticals Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by SyntheX Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Taiwan Liposome Company Ltd, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by tella Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by Tesaro Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Pipeline by VasGene Therapeutics Inc, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects, H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Bile Duct Cancer (Cholangiocarcinoma)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4SC AG

Advenchen Laboratories LLC

Agios Pharmaceuticals Inc

Ariad Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

AstraZeneca Plc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Cellular Biomedicine Group Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Delcath Systems Inc

Eisai Co Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genentech Inc

Genoscience Pharma

H3 Biomedicine Inc

Halozyme Therapeutics Inc

Hutchison MediPharma Ltd

Ignyta Inc

Immunitor Inc

Incyte Corp

Innopharmax Inc

Ipsen SA

Johnson & Johnson

Komipharm International Co Ltd

Leap Therapeutics Inc

Loxo Oncology Inc

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Molecular Templates Inc

Mundipharma International Ltd

NanoCarrier Co Ltd

NormOxys Inc

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Panacea Pharmaceuticals Inc

PCI Biotech Holding ASA

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Provecs Medical GmbH (Inactive)

Puma Biotechnology Inc

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

Sanofi

Senhwa Biosciences Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sirnaomics Inc

Sun Pharma Advanced Research Company Ltd

SynCore Biotechnology Co Ltd

Syndax Pharmaceuticals Inc

SyntheX Inc

Taiwan Liposome Company Ltd

tella Inc

Tesaro Inc

VasGene Therapeutics Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person